AAAAAA
Results:
1-8
|
Results: 8
Authors:
Ehrich, EW
Bolognese, JA
Watson, DJ
Kong, SX
Citation: Ew. Ehrich et al., Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis, AM J M CARE, 7(6), 2001, pp. 609-616
Authors:
Bolognese, JA
Ehrich, EW
Schnitzer, TJ
Citation: Ja. Bolognese et al., Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints, J RHEUMATOL, 28(12), 2001, pp. 2700-2704
Authors:
Hawkey, CJ
Laine, L
Harper, SE
Quan, HUI
Bolognese, JA
Mortensen, E
Citation: Cj. Hawkey et al., Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials, ALIM PHARM, 15(10), 2001, pp. 1593-1601
Authors:
Ehrich, EW
Davies, GM
Watson, DJ
Bolognese, JA
Seidenberg, BC
Bellamy, N
Citation: Ew. Ehrich et al., Minimal perceptible clinical improvement with the Western Ontario and McMaster universities osteoarthritis index questionnaire and global assessmentsin patients with osteoarthritis, J RHEUMATOL, 27(11), 2000, pp. 2635-2641
Authors:
Watson, DJ
Harper, SE
Zhao, PL
Quan, H
Bolognese, JA
Simon, TJ
Citation: Dj. Watson et al., Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis, ARCH IN MED, 160(19), 2000, pp. 2998-3003
Authors:
Hunt, RH
Bowen, B
Mortensen, ER
Simon, TJ
James, C
Cagliola, A
Quan, H
Bolognese, JA
Citation: Rh. Hunt et al., A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects, AM J MED, 109(3), 2000, pp. 201-206
Authors:
Lanza, FL
Rack, MF
Simon, TJ
Quan, H
Bolognese, JA
Hoover, ME
Wilson, FR
Harper, SE
Citation: Fl. Lanza et al., Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen, ALIM PHARM, 13(6), 1999, pp. 761-767
Authors:
Langman, MJ
Jensen, DM
Watson, DJ
Harper, SE
Zhao, PL
Quan, H
Bolognese, JA
Simon, TJ
Citation: Mj. Langman et al., Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs, J AM MED A, 282(20), 1999, pp. 1929-1933
Risultati:
1-8
|